Skip to content

A Prospective Study of Clinical and Imaging Characteristics and Construction of Predict Model for Recovered Dilated Cardiomyopathy

A Prospective Study of Clinical and Imaging Characteristics and Construction of Predict Model for Recovered Dilated Cardiomyopathy

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038869
Enrollment
Unknown
Registered
2020-10-08
Start date
2020-10-31
Completion date
Unknown
Last updated
2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dilated cardiomyopathy

Interventions

Gold Standard:Clinical outcome
Index test:A&#32
predictive&#32
model&#32
for&#32
recover&#32
after&#32
of&#32
patients&#32
with&#32
DCM&#32
by&#32
clinical,&#32
and&#32

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18 years or older and able to give written informed consent; 2. New-Onset DCM; 3. Clinically stable without a need for intravenous diuretic, vasoactive or inotropic therapy.

Exclusion criteria

Exclusion criteria: 1. Diagnosed with acquired dilated cardiomyopathy such as alcoholic cardiomyopathy, perinatal cardiomyopathy, tachycardia induced cardiomyopathy, etc.; 2. Severe and untreated or untreatable hypertension; 3. Severe CAD defined as a stenosis of > 70% in main coronary artery, or ischemia or a past history of myocardial infarction revealed by non-invasive modalities, or a history of CABG, coronary stent implement, AMI or unstable angina; 4. Structural heart disease, e,g., primary valvular disease, congenital heart disease; 5. Other systemic diseases that may affect the structure and function of the heart, such as hyperthyroidism, hypothyroidism, amyloidosis, pheochromocytoma, systemic lupus erythematosus, Behcet's disease, etc.; 6. Malignancy, severe infection, severe liver or kidney disease, or with an expected survival of less than 1 year; 7. Pregnant; 8. Claustrophobia; 9. Reluctance to participate.

Design outcomes

Primary

MeasureTime frame
Left ventricular ejection fraction;Left ventricular end-diastolic dimension;SEN, SPE, ACC, AUC of ROC, PPV, NPV;

Secondary

MeasureTime frame
NT-proBNP;Metabolic marker;

Countries

China

Contacts

Public ContactQing Zhang

West China Hospital, Sichuan University

qzhang2000cn@163.com+86 18980601267

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026